MRC1 and cancer: Patients with MMR tumor deficiency but no MMR germline pathogenic variant identified were slightly more likely to report no prior cancer compared to the reference group of MMR proficient cases, but this difference was not statistically significant (91.5% vs 85.7%, P = 0.07).